The Contribution of Luteinizing Hormone to Alzheimer Disease Pathogenesis

Overview

Journal Clin Med Res

Specialty General Medicine

Date 2007 Dec 7

PMID 18056027

Citations 14

Authors

Kate M Webber

George Perry

Mark A Smith

Gemma Casadesus

Affiliations

Soon will be listed here.

Abstract

Several hypotheses have been proposed that attempt to explain the pathogenesis of Alzheimer Disease (AD) including theories involving senile plaque and neurofibrillary tangle formation, increased oxidative stress, and cell cycle abnormalities, since evidence for each of these pathological phenomena have been well documented in AD. Recent epidemiological and experimental data also support a role for the gonadotropin luteinizing hormone in AD. Paralleling the female predominance for developing AD, luteinizing hormone levels are significantly higher in females as compared to males, and furthermore, luteinizing hormone levels are higher still in individuals who succumb to AD. Luteinizing hormone, which is capable of modulating cognitive behavior, is not only present in the brain, but also has the highest receptor levels in the hippocampus, a key processor of cognition that is severely deteriorated in AD. Furthermore, we recently examined cognitive performance in a well-characterized transgenic mouse that over-expresses luteinizing hormone and found that these animals show decreased cognitive performance when compared to controls. We have also found that abolishing luteinizing hormone in amyloid-beta protein precursor transgenic mice (Tg2576) using a potent gonadotropin-lowering gonadotropin-releasing hormone agonist, leuprolide acetate, resulted in improved hippocampally-related cognitive performance and decreased amyloid-beta deposition. These findings, together with data indicating that luteinizing hormone modulates amyloid-beta protein precursor processing in vivo and in vitro, suggest that luteinizing hormone may contribute to AD pathology through an amyloid-dependent mechanism. These promising findings support the importance of luteinizing hormone in AD and bring to the forefront an alternative, and much needed, therapeutic avenue for the treatment of this insidious disease.

Citing Articles

Transgenic Expressing Active Human LH Receptor in the Gonads Exhibit a Decreased Fecundity: Towards a Platform to Identify New Orally Active Modulators of Gonadotropin Receptor Activity.

Mahamid A, Ben-Menahem D Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458908 PMC: 11510345. DOI: 10.3390/ph17101267.

Luteinizing hormone is independently associated with high-sensitive cardiac troponin T elevation in postmenopausal T2DM patients: A cross-sectional study.

Wang Y, Li Y, Liu C, Wang Y, Li Y J Diabetes. 2024; 16(10):e70005.

PMID: 39436203 PMC: 11494916. DOI: 10.1111/1753-0407.70005.

CA-30, an oligosaccharide fraction derived from Liuwei Dihuang decoction, ameliorates cognitive deterioration via the intestinal microbiome in the senescence-accelerated mouse prone 8 strain.

Wang J, Lei X, Xie Z, Zhang X, Cheng X, Zhou W Aging (Albany NY). 2019; 11(11):3463-3486.

PMID: 31160541 PMC: 6594795. DOI: 10.18632/aging.101990.

On the central role of mitochondria dysfunction and oxidative stress in Alzheimer's disease.

Tobore T Neurol Sci. 2019; 40(8):1527-1540.

PMID: 30982132 DOI: 10.1007/s10072-019-03863-x.

LW-AFC, a new formula derived from Liuwei Dihuang decoction, ameliorates behavioral and pathological deterioration via modulating the neuroendocrine-immune system in PrP-hAβPPswe/PS1 transgenic mice.

Wang J, Lei X, Cheng X, Zhang X, Liu G, Cheng J Alzheimers Res Ther. 2016; 8(1):57.

PMID: 27964740 PMC: 5154149. DOI: 10.1186/s13195-016-0226-6.

References

Lindwall G, Cole R . Phosphorylation affects the ability of tau protein to promote microtubule assembly. J Biol Chem. 1984; 259(8):5301-5. View

Nagy Z, Esiri M, Smith A . Expression of cell division markers in the hippocampus in Alzheimer's disease and other neurodegenerative conditions. Acta Neuropathol. 1997; 93(3):294-300. DOI: 10.1007/s004010050617. View

Chen S, Nilsen J, Brinton R . Dose and temporal pattern of estrogen exposure determines neuroprotective outcome in hippocampal neurons: therapeutic implications. Endocrinology. 2006; 147(11):5303-13. DOI: 10.1210/en.2006-0495. View

Nagy Z, Esiri M, Cato A, Smith A . Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropathol. 1997; 94(1):6-15. DOI: 10.1007/s004010050665. View

Smith M . Alzheimer disease. Int Rev Neurobiol. 1998; 42:1-54. DOI: 10.1016/s0074-7742(08)60607-8. View

Jorm A, Jolley D . The incidence of dementia: a meta-analysis. Neurology. 1998; 51(3):728-33. DOI: 10.1212/wnl.51.3.728. View

Casadesus G, Garrett M, Webber K, Hartzler A, Atwood C, Perry G . The estrogen myth: potential use of gonadotropin-releasing hormone agonists for the treatment of Alzheimer's disease. Drugs R D. 2006; 7(3):187-93. DOI: 10.2165/00126839-200607030-00004. View

Mulnard . Estrogen as a treatment for alzheimer disease. JAMA. 2000; 284(3):307-8. View

Smith M, Perry G, Atwood C, Bowen R . Estrogen replacement and risk of Alzheimer disease. JAMA. 2003; 289(9):1100; author reply 1101-2. DOI: 10.1001/jama.289.9.1100-a. View

10.

Curcio F, Ceriello A . Decreased cultured endothelial cell proliferation in high glucose medium is reversed by antioxidants: new insights on the pathophysiological mechanisms of diabetic vascular complications. In Vitro Cell Dev Biol. 1992; 28A(11-12):787-90. DOI: 10.1007/BF02631069. View

11.

Smith M, Monnier V, Sayre L, Perry G . Amyloidosis, advanced glycation end products and Alzheimer disease. Neuroreport. 1995; 6(12):1595-6. DOI: 10.1097/00001756-199508000-00001. View

12.

Paoletti A, Congia S, Lello S, Tedde D, Orru M, Pistis M . Low androgenization index in elderly women and elderly men with Alzheimer's disease. Neurology. 2004; 62(2):301-3. DOI: 10.1212/01.wnl.0000094199.60829.f5. View

13.

Sherwin B . Estrogen and memory in women: how can we reconcile the findings?. Horm Behav. 2005; 47(3):371-5. DOI: 10.1016/j.yhbeh.2004.12.002. View

14.

Zhu X, Rottkamp C, Boux H, Takeda A, Perry G, Smith M . Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol. 2000; 59(10):880-8. DOI: 10.1093/jnen/59.10.880. View

15.

Iqbal K, Zaidi T, Thompson C, Merz P, Wisniewski H . Alzheimer paired helical filaments: bulk isolation, solubility, and protein composition. Acta Neuropathol. 1984; 62(3):167-77. DOI: 10.1007/BF00691849. View

16.

Schupf N, Kapell D, Nightingale B, Rodriguez A, Tycko B, Mayeux R . Earlier onset of Alzheimer's disease in men with Down syndrome. Neurology. 1998; 50(4):991-5. DOI: 10.1212/wnl.50.4.991. View

17.

Bowen R, Isley J, Atkinson R . An association of elevated serum gonadotropin concentrations and Alzheimer disease?. J Neuroendocrinol. 2000; 12(4):351-4. DOI: 10.1046/j.1365-2826.2000.00461.x. View

18.

Lalonde R . The neurobiological basis of spontaneous alternation. Neurosci Biobehav Rev. 2002; 26(1):91-104. DOI: 10.1016/s0149-7634(01)00041-0. View

19.

Chakravarti S, COLLINS W, Forecast J, Newton J, Oram D, Studd J . Hormonal profiles after the menopause. Br Med J. 1976; 2(6039):784-7. PMC: 1688678. DOI: 10.1136/bmj.2.6039.784. View

20.

Crisanti P, Omri B, Hughes E, Meduri G, Hery C, Clauser E . The expression of thyrotropin receptor in the brain. Endocrinology. 2001; 142(2):812-22. DOI: 10.1210/endo.142.2.7943. View